Fruit and Vegetable Products Enriched With Fibre From Potato Starch With Prebiotic Properties for Children and Youth
Development and Implementation of an Innovative Technology for the Production New Generation Fruit and Vegetable Products Enriched With Dietary Fibre Preparation From Potato Starch With Prebiotic Properties for Children and Youth
The main goal of the project is to test fruit and vegetable mousse, with the addition of a fiber preparation made of potato starch with prebiotic properties, on selected clinical, metabolic and immunological parameters in overweight and obese children.
The study will be performed in a group of 80 to 100 children aged 6 to 10 years (pre-pubertal age), using a double-blind procedure. Children will be randomly assigned into two groups, i.e. the intervention group (they will receive a vegetable and fruit mousse with the addition of potato starch fiber preparation with prebiotic properties) and the control group (they will receive an identical preparation in their diet, but without the addition of potato starch fiber preparation).
調査の概要
状態
詳細な説明
Purpose and nature of the study:
The study financed by the National Center for Research and Development is aimed at examining the vegetable and fruit mousse with the addition of a potato starch fiber preparation with prebiotic properties, in terms of preventing overweight and obesity in children and limiting the occurrence of metabolic disorders secondary to obesity.
Description of the procedures Children participating in the study will consume a daily fruit and vegetable mousse with or without the addition (control group) of a fiber-based potato starch preparation with prebiotic properties. Random selection will decide whether child will consume vegetable and fruit mousse with the addition of a fiber-based potato starch preparation with prebiotic properties. The study will be double blinded: neither parent and child, nor the attending physician will know whether the consumed mousse contains a fiber preparation. This method of conducting the study (random selection to the study group and control group and the so-called study blind) aims to eliminate the attitude of both the study participant and the observer to the therapy, which could affect the final assessment.
Children will take the mousse every day for six months (6 months). In order to evaluate the effect of fruit and vegetable mousse with the addition of a fiber preparation made of potato starch with prebiotic properties, the following tests will be performed: measurements of height, weight and, based on this measurements body mass index (BMI) will be calculated, waist circumference and blood pressure, bioimpedance test to assess the content of adipose and muscle tissue in the body, ultrasound of the carotid vessels and the liver, the speed of the pulse wave using the oscillometric method, the elastographic examination with a fibroscan, the examination of the composition of the intestinal flora in a stool sample, and a venous blood sample (7-10 ml volume) will be taken to evaluate lipid, carbohydrate metabolism, liver function, adipose tissue function, antioxidant status, and immune response parameters. The mentioned tests will be performed three times during the observation, i.e. at the time of enrollment in the study, after 6 months of taking the fruit and vegetable mousse and 3 months after the end of the vegetable and fruit mousse. In connection with participation in the study, the Child and Parents will be provided with dietary and physical activity advice as well as psychologist's advice on the day of enrollment in the study and at 3-month intervals up to 9 months from the start of participation in the study. Additionally, 3 months after starting taking the fruit and vegetable mousse, anthropometric and blood pressure measurements will be performed. During the participation in the study possible side effects will be registered.
A questionnaire containing questions about the child's date of birth, questions about the child's general health and taking medications, about the socio-demographic situation of the family, and food frequency questions will be completed.
研究の種類
入学 (予想される)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Piotr Socha, MD, PhD
- 電話番号:+48 501065154
- メール:p.socha@ipczd.pl
研究連絡先のバックアップ
- 名前:Zbigniew Kułaga, MD, PhD
- 電話番号:+48 603547517
- メール:zakulaga@gmail.com
研究場所
-
-
-
Warszawa、ポーランド、03-984
- 募集
- The Childen's Memorial Health Institute
-
コンタクト:
- Piotr Socha, Professor, MD, PhD
- 電話番号:+48 501 065 154
- メール:zakulaga@gmail.com
-
コンタクト:
- Zbigniew Zbigniew, MD, PhD
- 電話番号:603547517
- メール:zakulaga@gmail.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- overweight or obesity according to World Health Organization (WHO) definition
- in 20 patients additionally to overweight or obesity also increase blood pressure
- in 20 patients additionally to overweight or obesity also liver steatosis
- willingness to participate
Exclusion Criteria:
- allergy to mousse components
- malabsorption syndrome
- organ failure
- food neophobia
- other diseases or health problems which may interfere with study procedures or safety.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Intervention
Mousse with prebiotic
|
All children in the intervention group will consume on daily basis vegetable and fruit mousse enriched with a fiber preparation from potato starch with prebiotic properties for six months
All children in the study will obtain 4 dietary and physical activity advice during the course of the study
|
|
アクティブコンパレータ:Control
Mousse without prebiotic
|
All children in the study will obtain 4 dietary and physical activity advice during the course of the study
All children in the control group will consume on daily basis vegetable and fruit mousse for six months
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
BMI z-score change
時間枠:6 to 9 months
|
Change in age and sex standardized BMI z-scores
|
6 to 9 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Bioimpedance
時間枠:6 to 9 months
|
Change in body composition on bioimpedance (fat-body-mass %)
|
6 to 9 months
|
|
Waist
時間枠:6 to 9 months
|
Change in waist z-score (cm)
|
6 to 9 months
|
|
Gut microbiota
時間枠:6 to 9 months
|
change in microbiome composition
|
6 to 9 months
|
|
Triglyceride
時間枠:6 to 9 months
|
change in triglyceride-parameter of lipid metabolism (mg%)
|
6 to 9 months
|
|
Cholesterol
時間枠:6 to 9 months
|
change in cholesterol-parameter of lipid metabolism (mg%)
|
6 to 9 months
|
|
Low-density lipoprotein (LDL)
時間枠:6 to 9 months
|
change in Low-density lipoprotein (LDL)-parameter of lipid metabolism (mg%)
|
6 to 9 months
|
|
high-density lipoprotein (HDL)
時間枠:6 to 9 months
|
change in high-density lipoprotein (HDL)-parameter of lipid metabolism (mg%)
|
6 to 9 months
|
|
very low-density lipoprotein (VLDL)
時間枠:6 to 9 months
|
change in very low-density lipoprotein (VLDL)-parameter of lipid metabolism (mg%)
|
6 to 9 months
|
|
apolipoprotein
時間枠:6 to 9 months
|
change in apolipoprotein-parameter of lipid metabolism (mg%)
|
6 to 9 months
|
|
uric acid
時間枠:6 to 9 months
|
change in uric acid (mg%)
|
6 to 9 months
|
|
leptin
時間枠:6 to 9 months
|
change in leptin (ng/mL)
|
6 to 9 months
|
|
adiponectin
時間枠:6 to 9 months
|
change in adiponectin (ng/mL)
|
6 to 9 months
|
|
glucose, serum
時間枠:6 to 9 months
|
change in glucose (mg%)
|
6 to 9 months
|
|
insulin, serum
時間枠:6 to 9 months
|
change in insulin (mcIU/mL)
|
6 to 9 months
|
|
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
時間枠:6 to 9 months
|
change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), score, normal range<2,5
|
6 to 9 months
|
|
Glutathione (GSH)
時間枠:6 to 9 months
|
change in Glutathione (GSH) (g Hgb/mcL)
|
6 to 9 months
|
|
glutathione peroxidase (GPx)
時間枠:6 to 9 months
|
change in glutathione peroxidase (GPx) (mg/dL)
|
6 to 9 months
|
|
total antioxidant status (TAS)
時間枠:6 to 9 months
|
change in total antioxidant status (TAS) (mcmol/L)
|
6 to 9 months
|
|
tumor necrosis factor α (TNF-alfa)
時間枠:6 months
|
change in tumor necrosis factor α (TNF-alfa) (ng/mL)
|
6 months
|
|
interleukin 6 (IL-6)
時間枠:6 months
|
change in interleukin 6 (IL-6) (ng/mL)
|
6 months
|
|
Monocyte Chemoattractant Protein-1 (MCP-1)
時間枠:6 months
|
change in Monocyte Chemoattractant Protein-1 (MCP-1) (ng/mL)
|
6 months
|
|
Macrophage Inflammatory Protein-1 (MIP-1) alfa and beta
時間枠:6 months
|
change in Macrophage Inflammatory Protein-1 (MIP-1) alfa and beta (ng/mL)
|
6 months
|
|
Regulated upon Activation, Normal T Cell Expressed and Presumably Secreted (RANTES)
時間枠:6 months
|
change in Regulated upon Activation, Normal T Cell Expressed and Presumably Secreted (RANTES) (ng/mL)
|
6 months
|
|
lymphocyte T
時間枠:6 months
|
change in lymphocyte T (%)
|
6 months
|
協力者と研究者
出版物と役立つリンク
一般刊行物
- Barczynska R, Kapusniak J, Litwin M, Slizewska K, Szalecki M. Dextrins from Maize Starch as Substances Activating the Growth of Bacteroidetes and Actinobacteria Simultaneously Inhibiting the Growth of Firmicutes, Responsible for the Occurrence of Obesity. Plant Foods Hum Nutr. 2016 Jun;71(2):190-6. doi: 10.1007/s11130-016-0542-9.
- Barczynska R, Bandurska K, Slizewska K, Litwin M, Szalecki M, Libudzisz Z, Kapusniak J. Intestinal Microbiota, Obesity and Prebiotics. Pol J Microbiol. 2015;64(2):93-100.
- Barczynska R, Slizewska K, Litwin M, Szalecki M, Kapusniak J. Effects of dietary fiber preparations made from maize starch on the growth and activity of selected bacteria from the Firmicutes, Bacteroidetes, and Actinobacteria phyla in fecal samples from obese children. Acta Biochim Pol. 2016;63(2):261-6. doi: 10.18388/abp.2015_1068. Epub 2016 Feb 29.
- Litwin M, Sladowska J, Antoniewicz J, Niemirska A, Wierzbicka A, Daszkowska J, Wawer ZT, Janas R, Grenda R. Metabolic abnormalities, insulin resistance, and metabolic syndrome in children with primary hypertension. Am J Hypertens. 2007 Aug;20(8):875-82. doi: 10.1016/j.amjhyper.2007.03.005.
- Litwin M, Michalkiewicz J, Trojanek J, Niemirska A, Wierzbicka A, Szalecki M. Altered genes profile of renin-angiotensin system, immune system, and adipokines receptors in leukocytes of children with primary hypertension. Hypertension. 2013 Feb;61(2):431-6. doi: 10.1161/HYPERTENSIONAHA.111.00181. Epub 2012 Dec 24.
- Pinket AS, Van Lippevelde W, De Bourdeaudhuij I, Deforche B, Cardon G, Androutsos O, Koletzko B, Moreno LA, Socha P, Iotova V, Manios Y, De Craemer M; ToyBox-Study Group. Effect and Process Evaluation of a Cluster Randomized Control Trial on Water Intake and Beverage Consumption in Preschoolers from Six European Countries: The ToyBox-Study. PLoS One. 2016 Apr 11;11(4):e0152928. doi: 10.1371/journal.pone.0152928. eCollection 2016.
- Socha P, Grote V, Gruszfeld D, Janas R, Demmelmair H, Closa-Monasterolo R, Subias JE, Scaglioni S, Verduci E, Dain E, Langhendries JP, Perrin E, Koletzko B; European Childhood Obesity Trial Study Group. Milk protein intake, the metabolic-endocrine response, and growth in infancy: data from a randomized clinical trial. Am J Clin Nutr. 2011 Dec;94(6 Suppl):1776S-1784S. doi: 10.3945/ajcn.110.000596. Epub 2011 Aug 17.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
IPD 共有時間枠
IPD 共有アクセス基準
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。